Clinical trials: Metabolism Disorders
Dyslipidemia
A Long-term Study of ERN/LRPT (Extended Release Niacin/Laropiprant [MK0524A]) in Patients With Dyslipidemia (0524A-102)
This study will evaluate the efficacy of laropiprant (LRPT) to reduce flushing symptoms beyond 6 months and will measure the impact of withdrawal of laropiprant in patients following 20 weeks of stable maintenance therapy.
- Trial name
- NCT00961636
- Testing
- ER niacin (+) laropiprant (ERN/LRPT), Extended-release niacin (ERN)
- Volunteers
- 1,152 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 1
Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
The purpose of this study was to assess how glucagon administered nasally, using a nasal dosing delivery device, works in children and adolescents compared with commercially-available glucagon given by injection.
- Trial name
- NCT01997411
- Testing
- Nasal Glucagon, Intramuscular Glucagon
- Where
- 7 sites in United States
- Volunteers
- 48 people
- Sponsor
- Eli Lilly and Company
Child Obesity
Improving Parent-Child Interactions to Enhance Child Health
Childhood obesity is a formidable public health issue in the United States, disproportionately affecting children from lower socioeconomic status households.
- Trial name
- PCIT-Health (NCT03982511)
- Testing
- PCIT-Health
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Central Michigan University
Celiac Disease
Gluten Challenge Study in Celiac Disease Participants (MK-0000-402)
This is a gluten challenge study to characterize peripheral blood and intestinal gluten specific cluster of differentiation 4 glycoprotein (CD4+) thymus lymphocyte (T cell) subsets in participants with Celiac Disease
- Trial name
- NCT04054544
- Testing
- Gluten powder 4g
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Merck Sharp & Dohme LLC
Empaglifozin, Physiological Effects of Drugs
Sodium-glucose Co Transporter 2 (sGLT2) Inhibitor and Endogenous Ketone Production
Background: The drug empagliflozin treats diabetes. It lowers blood sugar by increasing glucose the kidneys excrete. This increases levels of ketones formed in the blood.
- Conditions
- Empaglifozin, Physiological Effects of Drugs, Hypoglycemic Agents, Sodium-Glucose Transporter 2 Inhibitors
- Trial name
- NCT03852901
- Testing
- empagliflozin (Jardiance) 25 mg
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Institute on Aging (NIA)
Non-alcoholic Fatty Liver Disease
Fucoidan Improves the Metabolic Profiles of Patients With Non-alcoholic Fatty Liver Disease (NAFLD)
Studies reveal special function of fucoidan so far include anti-virus, anti-tumor, immunomodulatory, anti-inflammatory, blood fat, anti-oxidation and liver and kidney dysfunction and improve fibrosis.
- Trial name
- NCT02875392
- Testing
- 275mg Oligo Fucoidan + 275mg HS Fucoxanthin
- Where
- Taiwan
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Taipei Medical University WanFang Hospital
Diabetes, Diabetes Mellitus, Type 2
Comparison of Biphasic Insulin Aspart 30 Versus Insulin Glargine Both in Combination With Metformin and Glimepiride in Subjects With Type 2 Diabetes
This trial is conducted in Africa, Asia, Europe, Oceania and South America. This trial aims for a comparison of biphasic insulin aspart 30 once daily versus insulin glargine once daily all in combination with metformin and…
- Trial name
- NCT00469092
- Testing
- biphasic insulin aspart, insulin glargine, metformin
- Where
- 69 sites in Argentina, Austria and 13 more
- Volunteers
- 480 people
- Sponsor
- Novo Nordisk A/S
Metabolic Syndrome
The Pick Two to Stick To Habit Development Intervention
Metabolic syndrome (MetS) is a leading risk factor for chronic disease among African American/Black populations. Fostering habit development offers a promising new approach to improving the effectiveness of lifestyle programs for…
- Trial name
- P2S2 (NCT03370419)
- Testing
- Treatment, Usual care
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Wayne State University
Obesity, Overweight
A Study of Tirzepatide in Overweight and Very Overweight Participants
The main purpose of this study is to measure the effect of tirzepatide on food intake in participants who are overweight or very overweight.
- Trial name
- NCT04311411
- Testing
- Tirzepatide, Liraglutide
- Where
- 3 sites in United States
- Volunteers
- 114 people
- Sponsor
- Eli Lilly and Company
Diabetes
Lifestyle Intervention in Overweight and Obese Pregnant Hispanic Women
The overall goal of this randomized controlled trial is to test the efficacy of a culturally and linguistically modified, individually tailored lifestyle intervention to reduce excess gestational weight gain (GWG), increase…
- Trial name
- NCT01868230
- Testing
- Lifestyle Intervention
- Where
- United States
- Volunteers
- 232 people, healthy volunteers welcome
- Sponsor
- University of Massachusetts, Amherst
Transfusional Hemosiderosis
Palatability and Tolerability of Deferasirox Taken With Meals, With Different Liquids or Crushed and Added to Food
This single-arm, open-label, multi-center study enrolled 65 patients from approximately 20 centers. All patients who met the study criteria and were taking, beginning or resuming treatment with Deferasirox were allowed.
- Trial name
- NCT00845871
- Testing
- deferasirox:
- Where
- 23 sites in United States
- Volunteers
- 65 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Kidney Disease, Metabolic Acidosis
Alkali Therapy in Chronic Kidney Disease
Kidney disease is a common medical condition. Individuals with kidney disease develop a build-up of acid in their blood. This acid can affect their muscles, bones, glucose metabolism and kidneys.
- Trial name
- NCT01452412
- Testing
- Sodium bicarbonate
- Where
- 2 sites in United States
- Volunteers
- 149 people
- Sponsor
- Albert Einstein College of Medicine
Diabetes, Diabetes Mellitus, Type 2
Comparison of the Change in Fat Distribution in Overweight and Obese Subjects With Type 2 Diabetes After Insulin Treatment
This trial is conducted in Europe. The aim of this clinical trial is to compare the change in trunk fat mass, assessed by Double Energy X-ray Absorptiometry (DEXA) after 26 weeks of treatment with insulin detemir or insulin NPH…
- Trial name
- NCT00795600
- Testing
- insulin detemir, insulin NPH
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- Novo Nordisk A/S
Metabolic Disease, Seizures
Phase 2 Clinical Trial of SGS-742 Therapy in Succinic Semialdehyde Dehydrogenase Deficiency
Objective: To perform a clinical trial assessing the safety, tolerability and efficacy of the GABA(B) receptor antagonist SGS-742 in patients with SSADH deficiency.
- Trial name
- NCT02019667
- Testing
- SGS-742
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Erythropoietic Protoporphyria
Phase III Confirmatory Study in Erythropoietic Protoporphyria
This is a randomized placebo-controlled study to be conducted in two parallel study arms for a six month period (three doses). Between 75 and 100 eligible patients will be enrolled.
- Trial name
- NCT01605136
- Testing
- Afamelanotide
- Where
- 7 sites in United States
- Volunteers
- 93 people
- Sponsor
- Clinuvel Pharmaceuticals Limited
Primary Hypercholesterolemia
Effects of Prescription Omega-3 on LDL-C in Primary Hypercholesterolemia
The objectives of this study are to assess the effects of 4 g/d P-OM3, compared with placebo, on LDL-C and other aspects of the fasting lipid profile in subjects with primary hypercholesterolemia.
- Trial name
- NCT00746811
- Testing
- P-OM3
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Provident Clinical Research
NASH - Nonalcoholic Steatohepatitis, Diabetes Mellitus, Type 2
Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus
The study in the T2DM population is intended to confirm the lanifibranor effect versus placebo on glycemic control and assess a positive effect of the combination of lanifibranor with an SGLT2 inhibitor on glycemic control.
- Trial name
- LEGEND (NCT05232071)
- Testing
- Lanifibranor, Empagliflozin
- Where
- 42 sites in United States, Belgium and 3 more
- Volunteers
- 39 people
- Sponsor
- Inventiva Pharma
Weight Loss, Obesity
Weight Management in Rural Communities
The goal of this study is to evaluate the effect of three weight management interventions (group phone conference calls, individual phone calls, and enhanced usual care) on weight across 18 months in overweight and obese adults…
- Conditions
- Weight Loss, Obesity, Body Weight
- Trial name
- M-DEx (NCT02932748)
- Testing
- Portion Controlled Meals (PCM), Group Phone (GP), Conventional Diet
- Where
- United States
- Volunteers
- 187 people
- Sponsor
- University of Kansas
Osteoporosis
Effects of Zoledronic Acid and Raloxifene on Bone Turnover Markers in Postmenopausal Women With Low Bone Mineral Density
This study will compare the effects of Zoledronic acid and Raloxifene in reducing bone turnover markers in postmenopausal women with low bone mineral density over 6 months.
- Trial name
- NCT00431444
- Testing
- Raloxifene, Zoledronic acid
- Where
- 17 sites in United States
- Volunteers
- 110 people
- Sponsor
- Novartis
Primary Hyperoxaluria, Primary Hyperoxaluria Type 1 (PH1)
A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1
The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of lumasiran in infants and young children with confirmed primary hyperoxaluria type 1 (PH1).
- Trial name
- ILLUMINATE-B (NCT03905694)
- Testing
- Lumasiran
- Where
- 9 sites in United States, France and 3 more
- Volunteers
- 18 people
- Sponsor
- Alnylam Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.